Association of Daily Growth Hormone Injection Adherence and Height Among Children With Growth Hormone Deficiency.
| Title: | Association of Daily Growth Hormone Injection Adherence and Height Among Children With Growth Hormone Deficiency. |
|---|---|
| Authors: | Loftus J; Pfizer Limited, Tadworth, Surrey, United Kingdom. Electronic address: jane.loftus@pfizer.com.; Miller BS; University of Minnesota Masonic Children's Hospital, Minneapolis, Minnesota.; Parzynski CS; Genesis Research, Hoboken, New Jersey.; Alvir J; Pfizer Inc., New York, New York.; Chen Y; Pfizer Inc., Collegeville, Pennsylvania.; Jhingran P; Genesis Research, Hoboken, New Jersey.; Gupta A; Pfizer Inc., New York, New York.; DeKoven M; IQVIA, Falls Church, Virginia.; Divino V; IQVIA, Falls Church, Virginia.; Tse J; IQVIA, Falls Church, Virginia.; He J; IQVIA, Falls Church, Virginia.; Wajnrajch M; Pfizer Inc., New York, New York; New York University Langone Medical Center, New York, New York. |
| Source: | Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists [Endocr Pract] 2022 Jun; Vol. 28 (6), pp. 565-571. Date of Electronic Publication: 2022 Mar 06. |
| Publication Type: | Journal Article |
| Language: | English |
| Journal Info: | Publisher: Elsevier Inc Country of Publication: United States NLM ID: 9607439 Publication Model: Print-Electronic Cited Medium: Print ISSN: 1530-891X (Print) Linking ISSN: 1530891X NLM ISO Abbreviation: Endocr Pract Subsets: MEDLINE |
| Imprint Name(s): | Publication: 2021- : [New York] : Elsevier Inc.; Original Publication: Jacksonville, Fla. : The College and the Association |
| MeSH Terms: | Dwarfism, Pituitary*/drug therapy ; Human Growth Hormone*/therapeutic use; Recombinant Proteins/therapeutic use ; Adult ; Body Height ; Child ; Female ; Growth Hormone ; Humans ; Male ; Medication Adherence ; Retrospective Studies |
| Abstract: | Objective: Recombinant human growth hormone (somatropin) is recommended for children with growth hormone deficiency (GHD) to normalize adult height. Prior research has indicated an association between adherence to somatropin and height velocity. Further research is needed using real-world data to quantify this relationship; hence the objective of this study was to investigate the association between adherence to somatropin and change in height among children with GHD.; Methods: This retrospective cohort study included patients in the IQVIA PharMetrics Plus and Ambulatory Electronic Medical Records databases aged 3 to 15 years, with ≥1 GHD diagnosis code claim and newly initiated on somatropin between January 1, 2007 and November 30, 2019. Adherence was measured over the follow-up using the medication possession ratio (MPR); patients were classified as adherent (MPR ≥ 0.8) or nonadherent (MPR < 0.8).; Results: Among 201 patients initiated on somatropin, 74.6% were male, mean age was 11.4 years, and the mean follow-up was 343.3 days. Approximately 76.6% of patients were adherent to somatropin over the follow-up period. Adjusted growth trajectories were similar between adherent and nonadherent patients pre-treatment initiation (P = .15). Growth trajectories post-initiation were significantly different (P = .001). On average, adherent patients gained an additional 1.8 cm over 1 year compared with nonadherent patients, adjusted for covariates.; Conclusion: Greater adherence to somatropin therapy is associated with improved height velocity. As suboptimal adherence to daily somatropin therapy is an issue for children with GHD, novel strategies to improve adherence may improve growth outcomes.; (Copyright © 2022 AACE. Published by Elsevier Inc. All rights reserved.) |
| Contributed Indexing: | Keywords: adherence; growth; height; pediatric growth hormone deficiency; somatropin |
| Substance Nomenclature: | 0 (Recombinant Proteins); 12629-01-5 (Human Growth Hormone); 9002-72-6 (Growth Hormone) |
| Entry Date(s): | Date Created: 20220309 Date Completed: 20220608 Latest Revision: 20220608 |
| Update Code: | 20260130 |
| DOI: | 10.1016/j.eprac.2022.02.013 |
| PMID: | 35263660 |
| Database: | MEDLINE |
Journal Article